Epilepsy is a debilitating illness which impacts the life of millions of people across the world. Tony Hitchcock of Cobra Biologics discusses how Cobra Biologics and CombiGene, a leading Nordic gene therapy company, are working for the development of plasmids and AAV-based gene therapy vectors, for their first treatment with the potential to dramatically improve the quality of life for a group of epilepsy patients for whom there is currently no effective treatment.

[wonderplugin_pdf src=”https://www.biopharmaceuticalmedia.com/wp-content/uploads/2020/07/Developing-Plasmid-DNA-Production-Platforms.pdf”]